NFATC1

Across TCGA pan-cancer cohorts, NFATC1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NFATC1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NFATC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where NFATC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.765	0.451	.011	15	view →
LUAD	DFS	Tertile	All	1.000	0.588	.004	15	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NFATC1–CCRCC (DFS)

Open the CCRCC breakdown →